Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Treatment Results and Prognostic Factors of Complicated Parapneumonic Effusion and Empyema

합병부폐렴삼출 및 농흉의 치료성적과 예후인자

  • Kim, Young-Joo (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Cha, Seung-Ick (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kwon, Jee-Suk (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Yoo, Seung-Soo (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Jun, Hee-Jung (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kim, Eun-Jin (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kim, Chang-Ho (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Park, Jae-Yong (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Jung, Tae-Hoon (Department of Internal Medicine, Kyungpook National University School of Medicine)
  • 김영주 (경북대학교 의과전문대학원 내과학교실) ;
  • 차승익 (경북대학교 의과전문대학원 내과학교실) ;
  • 권지숙 (경북대학교 의과전문대학원 내과학교실) ;
  • 유승수 (경북대학교 의과전문대학원 내과학교실) ;
  • 전희정 (경북대학교 의과전문대학원 내과학교실) ;
  • 김은진 (경북대학교 의과전문대학원 내과학교실) ;
  • 김창호 (경북대학교 의과전문대학원 내과학교실) ;
  • 박재용 (경북대학교 의과전문대학원 내과학교실) ;
  • 정태훈 (경북대학교 의과전문대학원 내과학교실)
  • Received : 2007.04.20
  • Accepted : 2007.07.04
  • Published : 2007.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Pleural effusion develops in approximately 40% of pneumonia patients. In 5-10% of these cases, it progresses to complicated parapneumonic effusion (CPPE) or empyema that requires drainage. The prognostic factors of CPPE and empyema remain to be clarified. We examined the treatment outcomes of CPPE and empyema and elucidating their prognostic factors. Methods: One hundred and fifteen patients with CPPE or empyema, who were diagnosed and treated in Kyungpook National University Hospital (Daegu, Korea) between September 2001 and December 2005, were retrospectively analyzed. All the data was acquired from their chart review, and regarding treatment results, the time to defervescence and the length of hospital stay were analyzed. Results: The treatment was successful in 101 patients with a success rate of 87.8%. Multivariate analysis showed the level of pleural fluid lactate dehydrogenase (LDH) to be a significant prognostic factor (odds ratio [OR] 7.37; 95% confidence interval [CI], 1.63 to 33.37; p=0.009). Pussy pleural fluid (r=0.236; p=0.01) and the frequency of urokinase use (r=0.257; p=0.01) correlated with the time to defervescence. However, there was no clinical factor that correlated with the length of hospital stay. Conclusion: The pleural fluid LDH level is a useful prognostic factor for monitoring treatment results of CPPE and empyema.

연구배경: 폐렴 환자 중 약 40%에서 흉막삼출이 동반되고 이 가운데 약 10%에서 배액이 필요한 합병부폐렴삼출 또는 농흉으로 진행된다. 저자들은 합병부폐렴삼출 및 농흉 환자에서 치료성적과 예후인자에 대해 알아보고자 하였다. 방 법: 2001년 9월부터 2005년 12월까지 합병부폐렴삼출 및 농흉으로 치료받았던 115명의 환자를 대상으로 후향적 연구를 시행하였다. 결 과: 대상환자 중 101예(87.8%)에서 치료성공을 보였는데 다변량분석에서 흉막액 LDH 수치(OR 7.37;95% CI, 1.63-33.37; p=0.009)가 치료성공 및 실패에 중요한 예후인자로 나타났다. 해열기간과 유의한 상관관계를 보인 인자로는 흉막액의 농성여부(r=0.236;p=0.01)와 섬유소용해물질 사용빈도(r=0.257; p=0.01)가 확인되었고 입원기간과 유의한 상관관계를 보인인자는 없었다. 결 론: 흉막액 LDH 수치가 합병부폐렴삼출 및 농흉에서 치료성적과 연관된 예후인자로 생각된다.

Keywords

References

  1. Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc 2006;3:75-80
  2. Hasley PB, Albaum MN, Li Y-H, Fuhrman CR, Britton CA, Marrie TJ, et al. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med 1996;156:2206-12 https://doi.org/10.1001/archinte.156.19.2206
  3. Andrews NC, Parker EF, Shaww RR, Wilson NJ, Webb WR. Management of nontuberculous empyema: a statement of the subcommittee on surgery. Am Rev Respir Dis 1962;85:935-6
  4. Hamm H, Light RW. Parapneumonic effusion and empyema. Eur Respir J 1997;10:1150-6 https://doi.org/10.1183/09031936.97.10051150
  5. Ozkan OS, Ozmen MN, Akhan O. Percutaneous management of parapneumonic effusions. Eur J Radiol 2005;55:311-20 https://doi.org/10.1016/j.ejrad.2005.03.004
  6. Kelly JW, Morris MJ. Empyema thoracis: medical aspects of evaluation and treatment. South Med J 1994;87:1103-10 https://doi.org/10.1097/00007611-199411000-00009
  7. Davies CW, Kearney SE, Gleeson FV, Davies RJ. Prediction of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999;160:1682-7 https://doi.org/10.1164/ajrccm.160.5.9903002
  8. Soriano T, Alegre J, Aleman C, Ruiz E, Vazquez A, Carrasco JL, et al. Factors influencing length of hospital stay in patients with bacterial pleural effusion. Respiration 2005;72:587-93 https://doi.org/10.1159/000087366
  9. Jimenez Castro D, Diaz G, Perez-Rodriguez E, Light RW. Prognostic features of residual pleural thickening in parapneumonic pleural effusions. Eur Respir J 2003;21:952-5 https://doi.org/10.1183/09031936.03.00099502
  10. Kim YS, Kim SM, Kim JH, Lee KS, Yang SC, Yoon HJ, et al. The effect of percutaneous pig-tail catheter drainage in the management of lung abscess and empyema. Tuberc Respir Dis 1996;43:571-8 https://doi.org/10.4046/trd.1996.43.4.571
  11. Chang JH. The evaluation of image-guided catheter drainage in pleural effusion and empyema. Tuberc Respir Dis 1996;43:403-9 https://doi.org/10.4046/trd.1996.43.3.403
  12. Park JW, You SM, Seol WJ, Paik EK, Lee KH, Seo JB, et al. Efficacy of pigtail catheter drainage in patients with thoracic empyema or complicated parapneumonic effusion. Tuberc Respir Dis 2003;54:219-29 https://doi.org/10.4046/trd.2003.54.2.219
  13. National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much. A clinician's guide. 2005 ed. Retrieved 28 December, 2006, from http://pubs.niaaa.nih.gov/publications/practitioner/clini ciansguide2005/clinicians_guide.htm
  14. Dawson DA, Grant BF, Li TK. Quantifying the risks associated with exceeding recommended drinking limits. Alcohol Clin Exp Res 2005;29:902-8 https://doi.org/10.1097/01.ALC.0000164544.45746.A7
  15. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score(SAPS II) based on European/North American multicenter study. JAMA 1993;270:2957-63 https://doi.org/10.1001/jama.270.24.2957
  16. Lemmer JH, Botham MJ, Orringer MB. Modern management of adult thoracic empyema. J Thorac Cardiovasc Surg 1985;90:849-55
  17. Huang HC, Chang HY, Chen CW, Lee CH, Hsiue TR. Predicting factors for outcome of tube thoracostomy in complicated parapneumonic effusion or empyema. Chest 1999;115:751-6 https://doi.org/10.1378/chest.115.3.751
  18. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bollinger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004;170:49-53 https://doi.org/10.1164/rccm.200312-1740OC
  19. Jensen EJ, Dahl R, Steffensen F. Bronchial reactivity to cigarette smoke: relation to lung function, respiratory symptoms, serum-immunoglobulin E and blood eosinophil and leukocyte counts. Respir Med 2000;94:119-27 https://doi.org/10.1053/rmed.1999.0664
  20. Mallampalli A, Guntupalli KK. Smoking and systemic disease. Clin Occup Environ Med 2006;5:173-92
  21. Froon AH, Bonten MJ, Gaillard CA, Greve JW, Dentener MA, de Leeuw PW, et al. Prediction of clinical severity and outcome of ventilator-associated pneumonia. Comparisonof simplified acute physiology score with systemic inflammatory mediators. Am J Respir Crit Care Med 1998;158:1026-31 https://doi.org/10.1164/ajrccm.158.4.9801013
  22. Aegerter P, Boumendil A, Retbi A, Minvielle E, Dervaux B, Guidet B. SAPS II revisited. Intensive Care Med 2005;31:416-23 https://doi.org/10.1007/s00134-005-2557-9
  23. Marra AR, Bearman GM, Wenzel RP, Edmond MB. Comparison of severity of illness scoring systems for patients with nosocomial blood stream infection due to Pseudomonas aerusinosa. BMC Infect Dis 2006;6:132 https://doi.org/10.1186/1471-2334-6-132
  24. Sikka P, Jaafar WM, Bozkanat E, El-solh AA. A comparison of severity of illness scoring systems for elderly patients with severe pneumonia. Intensive Care Med 2000;26:1803-10 https://doi.org/10.1007/s001340000719
  25. Misthos P, Sepsas E, Konstantinou M, Athanassiadi K, Skottis I, Iioulias A. Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. Eur J Cardiothorac Surg 2005;28:599-603 https://doi.org/10.1016/j.ejcts.2005.07.005
  26. Bouros D, Schiza S, Patsourakis G, Chalkiadakis G, Panagou P, Siafakas NM. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study. Am J Respir Crit Care Med 1997;155:291-5 https://doi.org/10.1164/ajrccm.155.1.9001327
  27. Bouros D, Schiza S, Tzanakis N, Drositis J, Siafakas N. Intrapleural urokinase in the treatment of complicated parapneumonic pleural effusions and empyema. Eur Respir J 1996;9:1656-9 https://doi.org/10.1183/09031936.96.09081656